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Abbreviations  
CENTRAL  Cochrane Central Register of Controlled Trials 
CI         Confidence interval 
CKD       Chronic kidney disease 
SD         Standard deviation 
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RCTs      Randomized controlled trials  
UGE       Urinary glucose excretion  
WMD      Weighted mean difference  
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Abstract 
Aim/hypothesis To examine whether and to what extent sodium glucose cotransporter 2 
(SGLT2) inhibitors affect serum electrolyte levels in type 2 diabetes patients by 
synthesizing available evidence from randomized controlled trials (RCTs). 
Methods We searched PubMed, Embase, CENTRAL, and ClinicalTrials.gov up to May 
24, 2016 for published RCTs of SGLT2 inhibitors that reported changes in serum 
electrolyte levels. Weighted mean difference (WMD) between each SGLT2 inhibitor and 
placebo was calculated using random-effects model. Dose-dependent relationships in 
each SGLT2 inhibitor were evaluated using meta-regression analysis. 
Results Eighteen eligible RCTs, including 15,309 patients and four SGLT2 inhibitors 
(canagliflozin, dapagliflozin, empagliflozin, and ipragliflozin) were evaluated. In patients 
without chronic kidney disease, each SGLT2 inhibitor significantly increased serum 
magnesium levels as compared with placebo (canagliflozin: WMD 0.06 mmol/l for 100 
mg and 0.09 mmol/l for 300mg; dapagliflozin: WMD 0.1 mmol/l for 10 mg; empagliflozin: 
WMD 0.04 mmol/l for 10 mg and 0.07 mmol/l for 25 mg; and ipragliflozin: WMD 0.05 
mmol/l for 50 mg). Canagliflozin seemed to increase serum magnesium in a linear 
dose-dependent manner (p=0.10). Serum phosphate was significantly increased by 
dapagliflozin, but serum sodium appeared to significantly differ by SGLT2 inhibitor type. 
No significant changes in serum calcium and potassium were observed. Findings were 
robust after including trials involving patients with chronic kidney disease. 
Conclusions/interpretation SGLT2 inhibitors marginally increased serum magnesium 
levels among type 2 diabetes patients, indicating a drug class effect.	Further 
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investigation is required to examine the clinical significance of elevating magnesium 
levels among type 2 diabetes patients. 
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Introduction 
Electrolyte abnormalities, usually caused by renal impairment, can lead to serious 
complications and even death. Sodium glucose cotransporter 2 (SGLT2) inhibitors are a 
novel class of glucose-lowering agents for treating type 2 diabetes by selectively 
inhibiting renal glucose reabsorption and increasing urinary glucose excretion (UGE) [1]. 
Because of increased UGE, SGLT2 inhibitor treatment may result in osmotic diuresis, 
which may trigger volume depletion and dehydration [2]. However, little is known about 
whether such hemodynamic changes caused by SGLT2 inhibitors influence renal 
electrolyte handling in patients with type 2 diabetes. We conducted a meta-analysis to 
synthesize available evidence from randomized controlled trials (RCTs) to examine 
whether and to what extent SGLT2 inhibitors affect serum electrolyte levels in patients 
with type 2 diabetes.  
Methods 
Search strategy and selection of articles We searched PubMed, Embase, Cochrane 
Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov up to May 24, 
2016 to identify eligible RCTs by using relevant search terms without restriction of 
language and year of publication (see ESM Table 1 for a complete list of search terms). 
We included parallel RCTs of at least 24 weeks’ duration that compared SGLT2 
inhibitors to placebo in adult patients with type 2 diabetes and reported mean (percent) 
changes from baseline of electrolyte levels in each group or other data to calculate these 
variances. Our primary outcomes were serum magnesium and secondary outcomes 
included serum sodium, phosphate, potassium, and calcium.  
Data extraction and quality assessment  We collected the following information from 
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each eligible RCT: first author (publication year), study characteristics (country of origin, 
design, and funding), patients’ characteristics (inclusion criteria, background treatments, 
mean age, pre-existing CKD disease, race, baseline glycated haemoglobin (HbA1c), 
mean estimated glomerular filtration rate, and body mean index), interventions (type and 
dose of SGLT2 inhibitor), and	the mean values (electrolyte level), variance measure, and 
the number of participants in the treatment and control arms for all reported periods.	
Mean (standard deviation) changes from baseline (mmol/l) for each SGLT2 inhibitor 
were extracted except canagliflozin, of which data were presented as mean (standard 
deviation) percent change from baseline (%) in the original article. The Cochrane risk of 
bias tool was used to assess the quality of RCTs based on 5 domains: random sequence 
generation (selection bias), allocation concealment (selection bias), blinding 
(performance bias and detection bias), incomplete outcome data (attrition bias), and 
selective reporting (reporting bias). Two reviewers (HT and XZ) independently extracted 
the data and assessed the quality of each RCT.	Any disagreements were resolved by 
consensus or referral to a third reviewer (YS).  
 
Statistical analysis Weighted mean differences (WMD) of serum electrolyte levels 
between each SGLT2 inhibitor and placebo with 95% confidence interval (CI) were 
calculated, using random effects meta-analysis models, evaluating each SGLT2 inhibitor 
separately, and by dose. Heterogeneity was quantified using the I² statistic, with I2 of 25, 
50, and 75 indicating low, medium, and high heterogeneity, respectively. A 
meta-regression analysis was employed to investigate any possible dose-dependent 
relationships between doses of each SGLT2 inhibitor and changes in serum electrolyte 
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levels [3]. The main meta-analysis was performed in patients without CKD. A sensitivity 
analysis additionally including the trials involving patients with CKD was performed. 
Publication bias was assessed using Begg’s test. All statistical analyses were performed 
with STATA (Version 14; Stata Corp., College Station, TX). 
Results 
Of 1,874 articles screened, 18 trials met eligibility criteria (ESM Fig 1), totaling 15,309 
unique participants [4-21]. Four SGLT2 inhibitors (canagliflozin, dapagliflozin, 
empagliflozin, and ipragliflozin) were evaluated. The duration of interventions ranged 
from 24 to 160 weeks (mean weeks: 67). Participants were generally middle-aged (mean 
age: 58), whites (14/18 studies), without CKD (16/18 studies) (ESM Table 2). Electrolyte 
concentrations at baseline fell within normal reference ranges in all studies (ESM Table 
3). Most included trials were judged as having a low risk of bias, except for one trial with 
high risk of bias for lacked blinding [10] (ESM Fig. 2).  
Serum magnesium levels significantly increased among canagliflozin users than among 
those receiving placebo (100 mg: WMD 8.03%, 95% CI: 6.89 to 9.16; 300 mg: WMD 
11.06%, 95%CI: 9.92 to12.19) (Fig 1). Canagliflozin seemed to increase serum 
magnesium in a dose- dependent manner (P for linear trend=0.10). Compared with 
placebo, only dapagliflozin 10 mg significantly increased serum magnesium (WMD 0.10 
mmol/l, 95%CI: 0.01 to 0.19). Empagliflozin significantly raised serum magnesium (10 
mg: WMD: 0.04 mmol/l, 95% CI: 0.02 to 0.07; 300 mg: WMD: 0.07 mmol/l, 95%CI: 0.04 
to 0.09), as did ipragliflozin 50 mg (WMD 0.05 mmol/l, 95%CI: 0.03 to 0.08). A sensitivity 
analysis additionally including 2 trials involving CKD patients showed that the results 
were robust. Statistically significant between-study heterogeneity was evident for 
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dapagliflozin and empagliflozin (I² >75%) but not for canaglifozin (I²=0%). There was no 
evidence of publication bias in this meta-analysis for serum magnesium (p>0.05).  
Compared with placebo, dapagliflozin 5 mg (WMD 0.04 mmol/l, 95%CI: 0.01 to 0.06) and 
dapagliflozin 10 mg (WMD 0.05 mmol/l, 95%CI: 0.02 to 0.09) significantly increased 
serum phosphate (Table 1 and ESM Fig. 3). Serum sodium levels were significantly 
higher among empagliflozin 25 mg users than among those receiving placebo (WMD 
0.31 mmol/l, 95%CI: 0.04 to 0.58). However, canagliflozin 300 mg seemed to decrease 
serum sodium levels (WMD -0.36 mmol/l, 95%CI: -0.68 to -0.05) (Table 1 and ESM Fig. 
4). No significant changes in serum calcium levels and potassium levels were observed 
among the patients using SLGT2 inhibitors (Table 1, ESM Fig. 5, and ESM Fig.6). A 
dose dependence relationship between doses of each SGLT2 inhibitors and these 
electrolytes levels was not observed. When additionally including the trials involving CKD 
patients, results were similar, except the comparison between empagliflozin 10 mg and 
placebo on change of serum sodium levels was significant (WMD 0.26 mmol/l, 95%CI: 
0.03 to 0.49). Heterogeneity was variable across SGLT2 type, doses, and electrolyte 
levels (Table 1).  
Discussion 
Our meta-analysis of 18 RCTs involving 15,309 patients provides the first robust 
evidence that SGLT2 inhibitors significantly increase serum magnesium levels among 
patients with type 2 diabetes; on average, serum magnesium levels were raised by 0.06 
mmol/l for canagliflozin 100 mg and 0.09 mmol/l for canagliflozin 300 mg, 0.1 mmol/l for 
dapagliflozin 10 mg, 0.04 mmol/l for empagliflozin 10 mg and 0.07 mmol/l for 
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empagliflozin 25 mg, and 0.05 mmol/l for ipragliflozin 50 mg. Taken together, the 
evidence indicates a drug class effect on serum magnesium levels. Effects on serum 
phosphate levels and serum sodium levels appear to differ by SGLT2 inhibitor type and 
dose. No significant effects on serum calcium levels and serum potassium levels were 
observed. 
Given that SGLT2 inhibitors induce glucosuria and osmotic diuresis, which may trigger 
volume depletion and dehydration, we hypothesized that changes in circulating 
electrolyte levels might occur with the use of such a new class of drugs. The significant 
elevation in serum magnesium levels, and the possibly increased phosphate levels, 
might be the result of osmotic diuresis caused by SGLT2 inhibitors, but the precise 
mechanisms are unknown. Abnormally high magnesium levels are predictive of total 
mortality in patients with heart failure [22], critically ill patients [23], and in those receiving 
haemodialysis [24]. Therefore, caution must to be exercised in those patients with 
disturbed renal function, such as severe CKD. On the other hand, in the general 
population and in those with type 2 diabetes, a gradient of risk for cardiovascular disease 
has been observed across the normal serum magnesium concentration range [25], with 
high-normal concentrations of serum magnesium associated with a lower risk of events 
[25]. Our meta-analysis found that a mean increase of 0.05 mmol/l in serum magnesium 
was significantly associated with a reduction in systolic blood pressure by 2.00 mm Hg 
and diastolic blood pressure by 1.78 mm Hg as compared with placebo [26]. If serum 
magnesium is causally related to cardiovascular risk, a modest increase in serum 
magnesium could have contributed to a reduction in cardiovascular mortality observed 
among patients with type 2 diabetes in the EMPA-REG OUTCOME trial [19]. However, 
10	
	
the observed changes in serum magnesium levels were, on average, within the 
physiological range. We do not know what proportion of individuals would have levels 
above the normal range, and therefore the clinical significance/interpretation of these 
data is uncertain. 
Changes in serum phosphate were also observed for dapagliflozin with a mean increase 
of 0.04 mmol/l and 0.05 mmol/l for 5 mg and 10 mg, respectively. The effects of 
increasing serum phosphate may have adverse effects on bone health by increasing 
secretion of parathyroid hormone, which enhances bone resorption and increases the 
risk of bone fractures [27]. Although one study showed that canagliflozin was associated 
with a decrease in bone mineral density at total hip in type 2 diabetes patients [28], the 
effect of SGLT2 inhibitors on fractures are still uncertain. It is interesting to find that 
serum sodium levels appear to differ by SGLT2 inhibitor type with a mean reduction of 
0.36 mmol/l for canagliflozin 300 mg and a mean increase of 0.31mmol/l for 
empagliflozin 25 mg. However, the clinical significant of small change in serum sodium 
levels less than 0.5 mmol/l was still unclear.   
Some limitations of our meta-analysis (e.g., low number of patients included in each 
SGLT2 inhibitor and statistically significant between-study heterogeneity) merit 
discussion, which reduced the strength of the evidence. In addition, we were unable to 
calculate the proportion of individuals who would have an abnormal electrolyte levels 
through taking SGLT2 inhibitors due to limit information from trials.  
In summary, SGLT2 inhibitors marginally increased serum magnesium levels among 
patients with type 2 diabetes. Dapagliflozin increased serum phosphate levels, but the 
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serum sodium levels appeared to differ between empagliflozin and canagliflozin. Further 
investigation is required to examine the clinical significance of changes in serum 
magnesium, phosphate, and sodium levels caused by SGLT2 inhibitors in patients with 
type 2 diabetes, especially those with several co-morbid chronic diseases.  
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Figure Legend:   1	
Fig. 1 Meta-analysis of standardized mean difference and 95% confidence interval in 2	
change in serum magnesium levels for each SGLT2 inhibitor versus placebo, stratified 3	
by dose.  4	
The WMD for canagliflozin was calculated as mean percent change from baseline (%) 5	
(a), and the other SGLT2 inhibitors were calculated as mean change from baseline 6	
(mmol/l) (b). The study of Rosenstock (2015) was excluded in the meta-analyses 7	
because of zero standard deviation. Note: weights are from random effects analysis. 8	
WMD, weighted mean difference; CI, confidence interval; N, number of patients; SD, 9	
standard deviation. 10	
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Table 1. Meta-analysis of weighted mean difference and 95% confidence interval in change of serum calcium, 11	
phosphate, potassium and sodium for each SGLT2 inhibitor versus placebo, stratified by dose. 12	
SGLT2 
inhibitor 
Serum calcium levels Serum phosphate levels Serum potassium levels Serum sodium levels 
  
n 
  
Nc 
WMD  
(95%CI) 
Het-I2% 
(95%CI) 
  
n 
  
Nc 
WMD 
(95%CI) 
Het-I2% 
(95%CI
) 
n 
  
Nc 
  
WMD 
(95%CI) 
Het-I2% 
(95%CI) 
n 
  
Nc 
  
WMD 
(95%CI) 
Het-I2% 
(95%CI) 
Canaglilfozina 
  100 mg - - - - 2 541 1.60 (-6.33,9.54) 90.3 3 1019
0.15 
(-0.88,1.17) 0 （0,90） 2 541 
 -0.22 
(-0.61,0.17) 34.3 
  300 mg - - - - 2   
541 
  
2.56 
(-3.32,8.44) 83.2 
3 
  
1014 
  
0.61 
(-1.45,2.27)
72 (5,  
92) 
2 
  
541 
  
 -0.36 
(-0.68,-0.05) 0 
Dapagliflozinb 
  2.5 mg 2   
535 
  
0.03 
(-0.02,0.08) 63 
2 
  
535 
  
0.01 
(-0.02,0.04) 0 
2 
  
535 
  
-0.02 
(-0.20,0.15) 69.5 
2 
  
535 
  
0.05 
(-0.68,0.77) 21.8 
  5 mg 2 543 0.00 (-0.03,0.03) 20.9 2 543 
0.04 
(0.01,0.06) 0 2 543 
-0.08 
(-0.17,0.01) 2.1 2 543 
0.49 
(-0.11,1.08) 0 
  10 mg 3   
712 
  
0.00 
(-0.03,0.03) 
46.6  
(0, 84) 
3 
  
712 
  
0.05 
(0.02,0.09) 
43.3 
(0, 83) 
3 
  
712 
  
-0.04 
(-0.20,0.13) 64.6 
2 
  
532 
  
0.37 
(-0.31,1.06) 0 
Empagliflozinb 
  10 mg 9   
7578 
  
0.00 
(-0.01,0.01) 
0   
(0,65)  
9 
  
7578 
  
0.02 
(-0.01,0.05) 
93 
(89,96
) 
9 
  
7578 
  
0.01 
(-0.02,0.04)
65.2 (29,  
83) 
9 
  
7578 
  
0.19 
(-0.03,0.49) 
77 
(56,88) 
  25 mg 9   
7552 
  
0.00 
(-0.01,0.01) 
0  
(0, 65)  
9 
  
7552 
  
0.02 
(-0.01,0.05) 
93 (89,  
96)  
9 
  
7552 
  
-0.00 
(-0.04,0.04)
76.7 
(56,88) 
9 
  
7552 
  
0.31 
(0.04,0.58) 
86.1 
(75,92) 
Ipragliflozinb 
  50 mg 1 170 -0.01 (-0.04,0.02) - 
1 
  
170 
  
0.13 
(-0.02,0.28) - 
1 
  
170 
  
0.02 
(-0.08,0.12) - 
1 
  
170 
  
0.00 
(-0.62,0.62) - 
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a mean percent change from baseline (%)  13	
b mean change from baseline (mmol/l)  14	
C safety analyses set 15	
- data not available 16	
   n, number of trials; N, number of patients; SGLT2, Sodium glucose cotransporter 2; WMD, weighted mean difference; 17	
CI, confidence interval; Het, heterogeneity 18	
 19	

